MétaCan
Menu
← Back to cohort
Record W4414445843 · doi:10.1101/2025.09.17.25335919

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma

2025· preprint· en· W4414445843 on OpenAlexaff
Tibor A. Zwimpfer, Sián Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa Jayawardana, Laura Twomey, Céline M. Laumont, Catherine J. Kennedy, Adelyn Bolithon, Nicola S. Meagher, Katy Milne, Phineas T. Hamilton, Jennifer Alsop, Antonis C. Antoniou, George Au‐Yeung, Matthias W. Beckmann, Amy Berrington de González, Christiani Bisinotto, Freya Blome, Clara Bodelón, Jessica Boros, Alison H. Brand, Michael E. Carney, Alicia Cazorla, Derek S. Chiu, Elizabeth L. Christie, Anita Chudecka-Głaz, Penny Coulson, Kara L. Cushing‐Haugen, Cezary Cybulski, Kathleen M. Darcy, C. W. Mabey David, Trent Davidson, Arif B. Ekici, Esther Elishaev, Julius Emons, Tobias Engler, Rhonda Farrell, Anna Fischer, Montserrat García‐Closas, Aleksandra Gentry‐Maharaj, Prafull Ghatage, Rosalind Glasspool, Philipp Harter, Andreas Hartkopf, Arndt Hartmann, Sebastian Heikaus, Brenda Y. Hernandez, Anusha Hettiaratchi, Sabine Heublein, David G. Huntsman, Mercedes Jimenez-Linan, Michael E. Jones, Eunyoung Kang, Ewa Kaznowska, Tomasz Kluz, F. Kommoss, Gottfried E. Konecny, Roy F.P.M. Kruitwagen, Diether Lambrechts, Cheng‐Han Lee, Jenny Lester, Samuel Leung, Yee Leung, Anna Linder, Jolanta Lissowska, Liselore Loverix, Jan Lubiński, Constantina Mateoiu, Iain A. McNeish, Malak Moubarak, Gregg Nelson, Nikilyn Nevins, Alexander Olawaiye, Siel Olbrecht, Sandra Oršulić, Ana Osório, Carmel M. Quinn, Ganendra Raj Mohan, Isabelle Ray‐Coquard, Cristina Rodríguez‐Antona, Patricia Roxburgh, Matthias Ruebner, Stuart Salfinger, Spinder Samra, Minouk J. Schoemaker, Hans‐Peter Sinn, Gabe S. Sonke, Linda Steele, Colin J.R. Stewart, Aline Talhouk, Adeline Tan, Christopher M. Tarney, Sarah E. Taylor, Koen Van de Vijver, Maaike A. van der Aa, Toon Van Gorp, Els Van Nieuwenhuysen, Lilian van‐Wagensveld, Andrea E. Wahner-Hendrickson, Christina B. Walter, Chen Wang, Julia Welz, Nicolas Wentzensen, Lynne R. Wilkens, Stacey J. Winham, Boris Winterhoff, Michael S. Anglesio, Andrew Berchuck, Francisco José Cândido dos Reis, Paul A. Cohen, Thomas P. Conrads, Philip Crowe, Jennifer A. Doherty, Peter A. Fasching, Renée T. Fortner, María J. García, Simon A. Gayther, Marc T. Goodman, Jacek Gronwald, Holly R. Harris, Florian Heitz, Hugo M. Horlings, Beth Y. Karlan, Linda E. Kelemen, G. Larry Maxwell, Usha Menon, Francesmary Modugno, Susan L. Neuhausen, Joellen M. Schildkraut, Annette Staebler, Karin Sundfeldt, Anthony J. Swerdlow, Ignace Vergote, Anna H. Wu, James D. Brenton, Paul D.P. Pharoah, Celeste Leigh Pearce, Malcolm C. Pike, Ellen L. Goode, Susan J. Ramus, Martin Köbel, Brad H. Nelson, Anna DeFazio, Michael Friedländer, David D.L. Bowtell, Dale W. Garsed

Bibliographic record

VenuemedRxiv · 2025
Typepreprint
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsUniversity of AlbertaUniversity of British ColumbiaFoothills Medical CentreBC Cancer AgencyVancouver General HospitalUniversity of CalgaryUniversity of Victoria
FundersNational Health and Medical Research CouncilMedical Research CouncilNational Institutes of HealthSeagenVerastem OncologyPeter MacCallum Cancer CentreF. Hoffmann-La RocheMedical Research and Materiel CommandMersana TherapeuticsAstraZeneca
KeywordsContext (archaeology)Serous fluidGermlineDiseaseCohortImmune systemSerous carcinomaOverall survival

Abstract

fetched live from OpenAlex

ABSTRACT BRCA -associated homologous recombination deficiency (HRD) is present in ∼50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA -deficient tumors experience unexpectedly poor outcomes. We profiled 154 tumors, enriched for patients with BRCA -deficient tumors that experienced short overall survival (≤3 years, n=42), using whole-genome, transcriptome, and methylation analyses. All but one BRCA -deficient tumor exceeded an accepted HRD genomic scarring threshold. However, patients with BRCA1 -deficient HGSC with a more elevated HRD score survived significantly longer. Patients with BRCA2 -deficient HGSC and loss of NF1 survived twice as long as those without NF1 loss, whereas PIK3CA or RAD21 amplification defined BRCA2 -deficient HGSC with exceptionally short survival. BRCA1 -deficient tumors in short survivors had evidence of immunosuppressive c-kit signaling and EMT. In a large HGSC cohort (n=1,389) including 282 individuals with pathogenic germline BRCA variants (g BRCA pv), the location of the mutation within functional domains stratified clinical outcomes. Notably, residual disease after primary surgery had limited prognostic effect in g BRCA pv-carriers compared to non-carriers. Our findings indicate that tumor HR proficiency in the context of therapy response and survival is not a binary property, and highlight genomic and immune modifiers of outcomes in BRCA -deficient HGSC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.277
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuemedRxiv→Same topicPARP inhibition in cancer therapy→French-language works237,207→